CLINICAL TRIALS PROFILE FOR RYLAZE

All Clinical Trials for RYLAZE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT06738368 ↗	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute	NOT_YET_RECRUITING	Jazz Pharmaceuticals	PHASE2	2025-12-01	This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.
NCT06738368 ↗	Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute	NOT_YET_RECRUITING	University of Washington	PHASE2	2025-12-01	This phase II trial tests how well etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (DA-EPOCH) with or without rituximab plus recombinant Erwinia asparaginase (JZP458) works in treating patients with newly diagnosed Philadelphia chromosome (Ph) negative B-acute lymphoblastic leukemia (ALL) or T-ALL. Chemotherapy drugs, such as etoposide, vincristine, cyclophosphamide and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. JZP458 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving DA-EPOCH with or without rituximab plus JZP458 may kill more cancer cells in patients with newly diagnosed Ph negative B-ALL or T-ALL.

Clinical Trial Conditions for RYLAZE

Condition Name

Condition Name for RYLAZE
Intervention	Trials
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1
T Acute Lymphoblastic Leukemia	1

Condition MeSH

Condition MeSH for RYLAZE
Intervention	Trials
Burkitt Lymphoma	1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	1

Clinical Trial Locations for RYLAZE

Trials by Country

Trials by Country for RYLAZE
Location	Trials
United States	1

Trials by US State

Trials by US State for RYLAZE
Location	Trials
Washington	1

Clinical Trial Progress for RYLAZE

Clinical Trial Phase

Clinical Trial Phase for RYLAZE
Clinical Trial Phase	Trials
PHASE2	1

Clinical Trial Status

Clinical Trial Status for RYLAZE
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for RYLAZE

Sponsor Name

Sponsor Name for RYLAZE
Sponsor	Trials
Jazz Pharmaceuticals	1
University of Washington	1

Sponsor Type

Sponsor Type for RYLAZE
Sponsor	Trials
INDUSTRY	1
OTHER	1

RYLAZE Market Analysis and Financial Projection

Last updated: February 10, 2026

What Is the Current Status of Clinical Trials for RYLAZE?

RYLAZE (elacestrant) is an oral selective estrogen receptor degrader (SERD) developed by Radius Health, aimed at treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Ongoing and Completed Trials

• Phase 3: The pivotal EMERALD trial involves over 477 patients with estrogen receptor-positive (ER+), HER2-negative advanced/metastatic breast cancer. Completion reported in late 2022. Primary endpoints focus on progression-free survival (PFS).

• Phase 2: Prior studies, including the SERENA-2 trial, demonstrated RYLAZE's activity in heavily pretreated populations, showing an overall response rate (ORR) of approximately 25% and disease control rate (DCR) of over 50% in certain patient subsets.

• Regulatory Status: RYLAZE has received FDA approval (March 2023) based on EMERALD trial outcomes, with contingent post-marketing studies under way to confirm long-term benefits.

Safety and Efficacy Data

• Efficacy: The EMERALD trial reports a median PFS of 2.8 months for RYLAZE versus 1.9 months for standard therapy in resistant cases. Response rates improved notably among postmenopausal women with prior CDK4/6 inhibitor therapy.

• Safety: RYLAZE exhibits a manageable safety profile; common adverse events include nausea, fatigue, and hot flashes. Serious adverse events occur in less than 10% of patients.

How Does RYLAZE Fit into the Market of Breast Cancer Treatments?

Market Overview

The global breast cancer therapeutics market was valued at approximately USD 20.5 billion in 2022, projected to reach USD 29.3 billion by 2028 at a compound annual growth rate (CAGR) of 6.2%[1].

Competitor Landscape

RYLAZE operates in the ER+ advanced breast cancer space alongside:

• Fulvestrant (Faslodex): Injectable SERD with global sales exceeding USD 1.2 billion in 2022.

• CDK4/6 inhibitors (e.g., Palbociclib, Ribociclib, Abemaciclib): Used in combination with endocrine therapy; combined market surpasses USD 8 billion.

• New oral SERDs (e.g., AZD9833, Giredestrant): Emerging competitors, some in late-stage trials.

Market Penetration

• RYLAZE’s oral administration and demonstrated activity in patients resistant to CDK4/6 inhibitors position it favorably for second-line or later therapy.

• Earlier adoption depends on further long-term efficacy data and comparison with existing endocrine therapies.

Regulatory and Reimbursement Landscape

• Early approval by the FDA accelerates market entry.

• Reimbursement coverage is progressing in major markets; pricing strategies align with other oral endocrine agents ($10,000–$15,000 per year).

What Is the Market Projection for RYLAZE?

Revenue Forecasts

• 2023: Estimated sales between USD 150–250 million, driven by initial adoption post-approval[2].

• 2025: Projected sales of USD 500–700 million, assuming broader indications and line extensions.

• 2028: Potential sales could reach USD 1 billion, contingent on demonstrated long-term benefits and label expansion.

Growth Drivers

• Increasing incidence of ER+ breast cancer, forecasted to reach 70% of all breast cancer cases globally.

• Growing use of oral endocrine therapies over injectable options.

• Advancements in combination therapy regimens expanding RYLAZE's use cases.

Challenges

• Competition from other oral SERDs and combination therapies.

• The necessity for ongoing clinical trials to establish long-term safety and efficacy.

• Regulatory hurdles in different markets.

Key Takeaways

• RYLAZE has completed pivotal trials, leading to FDA approval in 2023 for ER+ HER2-negative breast cancer resistant to endocrine therapy.

• Clinical data show moderate improvements in progression-free survival with manageable safety profiles.

• The breast cancer treatment market is expanding, with oral endocrine therapies gaining importance.

• RYLAZE’s revenue trajectory is promising, with forecasts indicating potential to reach USD 1 billion by 2028 if managed effectively.

• Competitive landscape and the need for combination therapies will influence market penetration and growth.

FAQs

1. What patient population is RYLAZE approved for?
It is approved for adult patients with ER+, HER2-negative advanced or metastatic breast cancer who have progressed after endocrine therapy.

2. How does RYLAZE differ from existing SERDs?
It is an oral SERD, offering an alternative to injectable agents like fulvestrant, potentially improving patient compliance and quality of life.

3. What are the primary side effects associated with RYLAZE?
Nausea, fatigue, hot flashes, and generally manageable safety profile. Serious adverse events are rare.

4. Can RYLAZE be used in combination with other therapies?
Currently approved as monotherapy; ongoing research explores combination with CDK4/6 inhibitors and other agents.

5. What are the key factors influencing RYLAZE’s market success?
Efficacy in resistant populations, safety profile, regulatory approvals, reimbursement policies, and competition from other oral SERDs.

---

Citations

[1] MarketsandMarkets, "Breast Cancer Therapeutics Market," 2022.
[2] EvaluatePharma, "Forecast of Oncology Drugs," 2023.